When the sphingosine kinase 1/sphingosine 1-phosphate pathway meets hypoxia signaling: New targets for cancer therapy

Cancer Research

Volumn 69, Issue 9, 2009, Pages 3723-3726

  Ader, Isabelle ^a,b   Malavaud, Bernard ^a,b,c   Cuvillier, Olivier ^a,b,d  

^a CNRS   (France)

^b UNIVERSITÉ DE TOULOUSE   (France)

^c CHU RANGUEIL   (France)

^d INSTITUT DE PHARMACOLOGIE ET DE BIOLOGIE STRUCTURALE   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; CAMPTOTHECIN DERIVATIVE; HYPOXIA INDUCIBLE FACTOR 1ALPHA; PROTEIN KINASE B INHIBITOR; SPHINGOSINE 1 PHOSPHATE; SPHINGOSINE KINASE 1; VASCULOTROPIN INHIBITOR;

ANGIOGENESIS; CANCER RESISTANCE; CANCER THERAPY; CELL HYPOXIA; CELL PROLIFERATION; CELL SURVIVAL; DRUG TARGETING; HUMAN; HYPOXIA; METASTASIS; NEOPLASM; NEOVASCULARIZATION (PATHOLOGY); NONHUMAN; OXYGEN TISSUE LEVEL; PRIORITY JOURNAL; PROTEIN ANALYSIS; REVIEW; SIGNAL TRANSDUCTION; SOLID TUMOR; TUMOR GROWTH;

ANIMALS; CELL HYPOXIA; DRUG DELIVERY SYSTEMS; HUMANS; HYPOXIA-INDUCIBLE FACTOR 1, ALPHA SUBUNIT; LYSOPHOSPHOLIPIDS; NEOPLASMS; PHOSPHOTRANSFERASES (ALCOHOL GROUP ACCEPTOR); SIGNAL TRANSDUCTION; SPHINGOSINE;

EID: 65949092331     PISSN: 00085472     EISSN: 15387445     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-09-0389     Document Type: Review

References (31)

1. Vaupel P, Mayer A. Hypoxia in cancer: significance and impact on clinical outcome. Cancer Metastasis Rev 2007;26:225-39. PubMed doi:10.1007/s10555-007- 9055-1.
2. Semenza GL. Hypoxia-inducible factor 1 and cancer pathogenesis. IUBMB Life 2008;60:591-7. PubMed doi:10.1002/iub.93.
3. Wang GL, Semenza GL. Purification and characterization of hypoxia-inducible factor 1. J Biol Chem 1995;270:1230-7. PubMed doi:10.1074/jbc.270.3.1230.
4. Kaelin WG, Jr., Ratcliffe PJ. Oxygen sensing by metazoans:the central role of the HIF hydroxylase pathway. Mol Cell 2008;30:393-402. PubMed doi:10.1016/j.molcel.2008.04.009.
5. Giaccia A, Siim BG, Johnson RS. HIF-1 as a target for drug development. Nat Rev Drug Discov 2003;2:803-11. PubMed doi:10.1038/nrd1199.
6. Liao D, Corle C, Seagroves TN, Johnson RS. Hypoxiainducible factor-1alpha is a key regulator of metastasis in a transgenic model of cancer initiation and progression. Cancer Res 2007;67:563-72. PubMed doi:10.1158/0008-5472. CAN-06-2701.
7. Melillo G. Targeting hypoxia cell signaling for cancer therapy. Cancer Metastasis Rev 2007;26:341-52. PubMed doi:10.1007/s10555-007-9059-x.
8. Spiegel S, Milstien S. Sphingosine-1-phosphate:an enigmatic signalling lipid. Nat Rev Mol Cell Biol 2003;4:397-407. PubMed doi:10.1038/nrm1103.
9. Cuvillier O, Pirianov G, Kleuser B, et al. Suppression of ceramide-mediated programmed cell death by sphingosine-1-phosphate. Nature 1996;381:800-3. PubMed doi:10.1038/381800a0.
10. Cuvillier O. Downregulating sphingosine kinase-1 for cancer therapy. Expert Opin Ther Targets 2008;12:1009-20. PubMed doi:10.1517/14728222.12.8.1009.
11. Jin ZQ, Goetzl EJ, Karliner JS. Sphingosine kinase activation mediates ischemic preconditioning in murine heart. Circulation 2004;110:1980-9. PubMed doi:10.1161/01. CIR.0000143632.06471.93.
12. Pchejetski D, Kunduzova O, Dayon A, et al. Oxidative stress-dependent sphingosine kinase-1 inhibition mediates monoamine oxidase A-associated cardiac cell apoptosis. Circ Res 2007;100:41-9. PubMed doi:10.1161/01. RES.0000253900.66640.34.
13. Tao R, Zhang J, Vessey DA, Honbo N, Karliner JS. Deletion of the sphingosine kinase-1 gene influences cell fate during hypoxia and glucose deprivation in adult mouse cardiomyocytes. Cardiovasc Res 2007;74:56-63. PubMed doi:10.1016/j.cardiores.2007.01.015.
14. Yun JK, Kester M. Regulatory role of sphingomyelin metabolites in hypoxia-induced vascular smooth muscle cell proliferation. Arch Biochem Biophys 2002;408:78-86. PubMed doi:10.1016/S0003-9861 (02) 00526-X.
15. Ahmad M, Long JS, Pyne NJ, Pyne S. The effect of hypoxia on lipid phosphate receptor and sphingosine kinase expression and mitogen-activated protein kinase signaling in human pulmonary smooth muscle cells. Prostaglandins Other Lipid Mediat 2006;79:278-86. PubMed doi:10.1016/j.prostaglandins.2006.03. 001.
16. Ader I, Brizuela L, Bouquerel P, Malavaud B, Cuvillier O. Sphingosine kinase 1:a new modulator of hypoxia inducible factor 1alpha during hypoxia in human cancer cells. Cancer Res 2008;68:8635-42. PubMed doi:10.1158/0008-5472. CAN-08-0917.
17. Skuli N, Monferran S, Delmas C, et al. Activation of RhoB by hypoxia controls hypoxia-inducible factor- 1alpha stabilization through glycogen synthase kinase-3 in U87 glioblastoma cells. Cancer Res 2006;66:482-9. PubMed doi:10.1158/0008-5472. CAN-05-2299.
18. Wang GL, Jiang BH, Rue EA, Semenza GL. Hypoxiainducible factor 1 is a basic-helix-loop-helix-PAS heterodimer regulated by cellular O2 tension. Proc Natl Acad Sci U S A 1995;92:5510-4. PubMed doi:10.1073/pnas.92.12.5510.
19. Wiesener MS, Jurgensen JS, Rosenberger C, et al. Widespread hypoxia-inducible expression of HIF-2alpha in distinct cell populations of different organs. FASEB J 2003;17:271-3. PubMed.
20. Kaelin WG, Jr. Kidney cancer:now available in a new flavor. Cancer Cell 2008;14:423-4. PubMed doi:10.1016/j.ccr.2008.11.005.
21. Gordan JD, Lal P, Dondeti VR, et al. HIF-alpha effects on c-Myc distinguish two subtypes of sporadic VHL- deficient clear cell renal carcinoma. Cancer Cell 2008;14:435-46. PubMed doi:10.1016/j.ccr.2008.10.016.
22. Anelli V, Gault CR, Cheng AB, Obeid LM. Sphingosine kinase 1 is up-regulated during hypoxia in U87MG glioma cells:role of hypoxia-inducible factors 1 and 2. J Biol Chem 2008;283:3365-75. PubMed doi:10.1074/jbc. M708241200.
23. Melillo G. Hypoxia-inducible factor 1 inhibitors. Methods Enzymol 2007;435:385-402. PubMed doi:10.1016/S0076-6879 (07) 35020-9.
24. Semenza GL. Evaluation of HIF-1 inhibitors as anticancer agents. Drug Discov Today 2007;12:853-9. PubMed doi:10.1016/j.drudis.2007.08.006.
25. Winkler F, Kozin SV, Tong RT, et al. Kinetics of vascular normalization by VEGFR2 blockade governs brain tumor response to radiation:role of oxygenation, angiopoietin-1, and matrix met alloproteinases. Cancer Cell 2004;6:553-63. PubMed.
26. Pore N, Gupta AK, Cerniglia GJ, et al. Nelfinavir down-regulates hypoxia-inducible factor 1alpha and VEGF expression and increases tumor oxygenation:implications for radiotherapy. Cancer Res 2006;66:9252-9. PubMed doi:10.1158/0008-5472. CAN-06-1239.
27. Jain RK. Normalization of tumor vasculature:an emerging concept in antiangiogenic therapy. Science 2005;307:58-62. PubMed doi:10.1126/science. 1104819.
28. Lee MJ, Thangada S, Claffey KP, et al. Vascular endothelial cell adherens junction assembly and morphogenesis induced by sphingosine-1-phosphate. Cell 1999;99:301-12. PubMed doi:10.1016/S0092-8674 (00) 81661-X.
29. Garcia JG, Liu F, Verin AD, et al. Sphingosine 1-phosphate promotes endothelial cell barrier integrity by Edg-dependent cytoskelet al. rearrangement. J Clin Invest 2001;108:689-701. PubMed.
30. Sanchez T, Skoura A, Wu MT, Casserly B, Harrington EO, Hla T. Induction of vascular permeability by the sphingosine-1-phosphate receptor-2 (S1P2R) and its downstream effectors ROCK and PTEN. Arterioscler Thromb Vasc Biol 2007;27:1312-8. PubMed doi:10.1161/ATVBAHA.107.143735.
31. Visentin B, Vekich JA, Sibbald BJ, et al. Validation of an anti-sphingosine-1-phosphate antibody as a potential therapeutic in reducing growth, invasion, and angiogenesis in multiple tumor lineages. Cancer Cell 2006;9:225-38. PubMed doi:10.1016/j.ccr.2006.02.023.